Effect of Body Position on Spirometry in Abdominal Obesity.
NCT ID: NCT03347604
Last Updated: 2019-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2017-10-06
2018-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background: Spirometry is routinely ordered to work up dyspnea in obesity. The most common abnormality is a restrictive disease pattern. The underlying mechanisms of this pattern are not completely understood. One plausible explanation is diaphragmatic weakness or skeletal muscle weakness. The change in forced vital capacity (FVC) from sitting to supine is a very sensitive and specific test for detecting diaphragmatic weakness. The effect of body position on spirometry in obesity has not been extensively studied, and there are no studies that look at this when obesity is measured by waist to hip ratio. Effect of body position has been studied in normal patients, and it is expected the FVC can decrease as much as 10% when changing from sitting to supine. The investigators do not know what would be considered 'the normal' amount for FVC to decrease by in the obese population, and thus would like to test patients with increased WHR both in sitting and supine position. The investigators also want to do muscle strength test by measuring the maximal inspiratory and expiratory pressures (MIPs and MEPs).
Anticipated results: the investigators anticipate that our study population will replicate the restrictive disease pattern usually seen in obesity. The investigators also anticipate for the FVC to decrease when in the supine position compared to sitting. The amount by which it decreases will likely fall between 10 -25%. The investigators anticipate to not find any abnormalities in MIPs and MEPs in obesity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EVALUATION OF RESPIRATORY MECHANICS AND FUNCTIONALITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NCT03086590
Comparison of Anterior Chest Compression Assist and Abdominal Thrust Assist Technique COPD
NCT05936801
Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity
NCT03836547
Effect of Expiratory Positive Pressure on Dynamic Hyperinflation and Ability to Exercise With Upper Limbs in COPD
NCT03073564
Abdominal Binding in Chronic Obstructive Pulmonary Disease
NCT01852006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The BMI (kg/m2) will be calculated as weight (in kilograms) divided by square of the height (in meters). Waist-hip ratio (WHR) will be measured in the standing position using a stretch-resistant tape. Waist circumference will be measured at a midpoint between the lowest rib and the middle of the iliac crest. The hip is defined as the maximal circumference around the gluteal muscles below the iliac crests.8,9 These measurements will be obtained by respiratory therapists who have been trained in obtaining WHR measurements using a standardized patient to assure measurement fidelity.
Spirometry measurements of FEV1 and FVC will be made in two testing positions for this study; the patients seated 90o upright (sitting position), and the patient fully supine position (0ยบ horizontal decubitus position). FVC (forced vital capacity) is the volume of air in liters that can be forcibly and maximally exhaled after taking in the deepest breath. FEV1 is the volume of air that can be forcibly exhaled from the lungs in the first second of a forced expiratory maneuver and is reported in liters. Lung volumes will also be measured in the sitting position using either body plethysmography or nitrogen washout method as part of the routine CPFT testing. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), will also be measured in the sitting position and reported in centimeters of water (cm H2O). These reflect the maximum pressures generated by the patient on inhalation and exhalation, respectively and test respiratory muscle strength. All tests will be conducted in accordance with 2005 American Thoracic Society/European Respiratory Society guidelines13 using the Sensormedics Vmax pulmonary function system. The Vmax system is calibrated daily and reports all measurements at body temperature, pressure and water vapor. All tests will be performed by a team of respiratory therapists who have demonstrated annual competence following the recommendations of the American Thoracic Society/European Respiratory Society.14
Individuals who meet the study criteria and are able to successfully complete a CPFT will be recruited to participate in the study. After completing a consent form, the waist and hip measurements will be made. MIP and MEP measures will be made in the sitting position. Testing of spirometry will be repeated in the supine position. Sitting FEV1, FEV1 % predicted, FVC, FVC % predicted, FEV1/SVC, lower limit of normal for FEV1/FVC, supine FEV1, FEV1 % predicted, FVC, FVC % predicted, MIP, MEP, ERV, RV, FRC and TLC will be extracted from the pulmonary function test results and entered in REDCap for data tracking. Age, race, gender, and diagnosis code will be taken from the information routinely gathered for a pulmonary function test. The question related to smoking history will be asked directly of the subject. All data will be entered into REDCap.
Procedures done for research purposes and procedures done for routine clinical management:
A routine complete pulmonary function test (CPFT) as ordered by their referring provider includes measurements of slow vital capacity by spirometry, forced vital capacity by spirometry, lung diffusion by DLCO, and measurement of lung volume by body plethysmography. All of these measurements will be performed while the patient in sitting position. The additional testing for this study includes spirometry while the patient is in the supine position; and MIPs, and MEPs in the sitting position.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with abdominal obesity
Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of \> 0.85 in women, or \> 0.9 in men.
Supine spirometry, MIPs and MEPs
We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supine spirometry, MIPs and MEPs
We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals with abdominal obesity with WHR \> 0.85 in women, \> 0.9 in men
* Ability of patients to transfer themselves into a cardiac chair
* Able to understand and comply with testing instructions
Exclusion Criteria
* Patients who are unable to perform an acceptable and repeatable forced vital capacity
* Airflow limitation as evidenced by sitting FEV1/VC \< lower limit of normal
* Patients who have a WHR \< 0.85 in women, or \< 0.9 in men
* Patients who become lightheaded during sitting spirometry
* Patients who cannot transfer themselves independently to a cardiac chair
* History of lung disease (known obstructive or restrictive lung disease)
* Chest wall abnormalities or kyphoscoliosis
* Neuromuscular disease
* Active hemoptysis or recent angina
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antranik Mangardich
Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994 Jul 20;272(3):205-11. doi: 10.1001/jama.272.3.205.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
Guilbert JJ. The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon). 2003 Jul;16(2):230. doi: 10.1080/1357628031000116808. No abstract available.
Wing RR, Matthews KA, Kuller LH, Meilahn EN, Plantinga P. Waist to hip ratio in middle-aged women. Associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors. Arterioscler Thromb. 1991 Sep-Oct;11(5):1250-7. doi: 10.1161/01.atv.11.5.1250.
Saxena Y, Sidhwani G, Upmanyu R. Abdominal obesity and pulmonary functions in young Indian adults: a prospective study. Indian J Physiol Pharmacol. 2009 Oct-Dec;53(4):318-26.
Harik-Khan RI, Wise RA, Fleg JL. The effect of gender on the relationship between body fat distribution and lung function. J Clin Epidemiol. 2001 Apr;54(4):399-406. doi: 10.1016/s0895-4356(00)00318-8.
Al Ghobain M. The effect of obesity on spirometry tests among healthy non-smoking adults. BMC Pulm Med. 2012 Mar 21;12:10. doi: 10.1186/1471-2466-12-10.
Koenig SM. Pulmonary complications of obesity. Am J Med Sci. 2001 Apr;321(4):249-79. doi: 10.1097/00000441-200104000-00006.
TUCKER DH, SIEKER HO. The effect of change in body position on lung volumes and intrapulmonary gas mixing in patients with obesity, heart failure, and emphysema. Am Rev Respir Dis. 1960 Dec;82:787-91. doi: 10.1164/arrd.1960.82.6.787. No abstract available.
BLAIR E, HICKAM JB. The effect of change in body position on lung volume and intrapulmonary gas mixing in normal subjects. J Clin Invest. 1955 Mar;34(3):383-9. doi: 10.1172/JCI103086. No abstract available.
Shimokata H, Andres R, Coon PJ, Elahi D, Muller DC, Tobin JD. Studies in the distribution of body fat. II. Longitudinal effects of change in weight. Int J Obes. 1989;13(4):455-64.
Sievenpiper JL, Jenkins DJ, Josse RG, Leiter LA, Vuksan V. Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. Am J Clin Nutr. 2001 Mar;73(3):567-73. doi: 10.1093/ajcn/73.3.567.
Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. doi: 10.1183/09031936.05.00034505. No abstract available.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991 Nov;144(5):1202-18. doi: 10.1164/ajrccm/144.5.1202. No abstract available.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5-40. No abstract available.
Ceylan E, Comlekci A, Akkoclu A, Ceylan C, Itil O, Ergor G, Yesil S. The effects of body fat distribution on pulmonary function tests in the overweight and obese. South Med J. 2009 Jan;102(1):30-5. doi: 10.1097/SMJ.0b013e31818c9585.
Chen Y, Rennie D, Cormier YF, Dosman J. Waist circumference is associated with pulmonary function in normal-weight, overweight, and obese subjects. Am J Clin Nutr. 2007 Jan;85(1):35-9. doi: 10.1093/ajcn/85.1.35.
Domingos-Benicio NC, Gastaldi AC, Perecin JC, Avena KM, Guimaraes RC, Sologuren MJ, Lopes-Filho JD. [Spirometric values of obese and non-obese subjects on orthostatic, sitting and supine positions]. Rev Assoc Med Bras (1992). 2004 Apr-Jun;50(2):142-7. doi: 10.1590/s0104-42302004000200028. Epub 2004 Jul 21. Portuguese.
Magnani KL, Cataneo AJ. Respiratory muscle strength in obese individuals and influence of upper-body fat distribution. Sao Paulo Med J. 2007 Jul 5;125(4):215-9. doi: 10.1590/s1516-31802007000400004.
Al-Bader WR, Ramadan J, Nasr-Eldin A, Barac-Nieto M. Pulmonary ventilatory functions and obesity in Kuwait. Med Princ Pract. 2008;17(1):20-6. doi: 10.1159/000109585.
Bae J, Ting EY, Giuffrida JG. The effect of changes in the body position obsese patients on pulmonary volume and ventilatory function. Bull N Y Acad Med. 1976 Sep;52(7):830-7. No abstract available.
Vilke GM, Chan TC, Neuman T, Clausen JL. Spirometry in normal subjects in sitting, prone, and supine positions. Respir Care. 2000 Apr;45(4):407-10.
Lechtzin N, Wiener CM, Shade DM, Clawson L, Diette GB. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest. 2002 Feb;121(2):436-42. doi: 10.1378/chest.121.2.436.
Fromageot C, Lofaso F, Annane D, Falaize L, Lejaille M, Clair B, Gajdos P, Raphael JC. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil. 2001 Jan;82(1):123-8. doi: 10.1053/apmr.2001.18053.
Teixeira AB, Mathias LA, Saad Junior R. The influence of posture on spirometric values in grade III obese patients. Rev Bras Anestesiol. 2011 Nov-Dec;61(6):713-9. doi: 10.1016/S0034-7094(11)70080-0. English, Multiple languages.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ORA: 17060206-IRB01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.